Neurocrine Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Neurocrine Biosciences sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
Neurocrine Biosciences: 65 sponsored US clinical trials, 12 recruiting.
Neurocrine Biosciences sponsors 65 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 42 completed. 23 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 6 trials.
Top-decile sponsor footprint
Neurocrine Biosciences ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
42 of 48 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
65 total, page 2 of 2
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
NCT02736955
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
NCT02748694
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02679079
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02581865
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
NCT02405091
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
NCT02274558
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02256475
Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease
NCT01973543
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
NCT01916993
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects
NCT01910480
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
NCT01733121
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
NCT01688037
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
NCT01393600
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
NCT00039052
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00014677
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 27 |
| Phase 3 | 19 |
| Phase 4 | 4 |
What is open in the Neurocrine Biosciences pipeline
12 recruiting of 65 indexed (18% open); 42 completed (65%).
Phase mix: 23 late (III/IV) vs 40 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Neurocrine Biosciences: open-pipeline peers nationwide
Peers matched on 65 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Neurocrine Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 trials (± recruiting share)
- BeiGene · 65 trials · 14% recruiting
- Glaxo Wellcome · 65 trials · 0% recruiting
- LEO Pharma · 65 trials · 5% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of California, San Diego · 18% recruiting · 775 trials
- Thomas Jefferson University · 18% recruiting · 292 trials
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Florida Atlantic University · 19% recruiting · 27 trials
Related
What to do with this Neurocrine Biosciences page
65 registered trials is a research-attention snapshot, not an endorsement of Neurocrine Biosciences or any single study.
- 12 of Neurocrine Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Neurocrine Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Neurocrine Biosciences pipeline card: 65 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.